Başak KARBEK, Erman ÇAKAL, Aşkın GÜNGÜNEŞ, Evrim ÖNDER, Taner DEMİRCİ, Bekir UÇAN, İlknur ÜNSAL ÖZTÜRK, Esra AKKAYA TUTAL, Tuncay DELİBAŞI, Müyesser ARSLAN SAYKI, Oya TOPALOĞLU

Sitagliptin Kullanımına Bağlı Gelişen Kütanöz Lökositoklastik Vaskülit: Olgu sunumu

Sitagliptin inkretin hormon sistemi üzerinden etki eden, DPP-IV inhibitörü grubundan, diabetes mellitus (DM) te- davisinde kullanılan yeni jenerasyon bir ajandır. Tek başına kullanıldığında hipoglisemiye neden olmamaları ilekilo alımı üzerine nötr etkileri gibi avantajları vardır. En sık yan etki olarak baş ağrısı, farenjit görülür ve klinikçalışmalarda bazı ciddi istenmeyen olaylara (akut karaciğer hasarı, renal yetmezlik, rabdomiyoliz) neden olduğugösterilmiştir. Sitagliptin ve metabolitleri allerji ve hipersensitivite reaksiyonlarına neden olabilmektedir. Sitagliptinile ilişkili kutanöz lökositoklastik vaskülit daha önce literatürde tanımlanmamıştır. Bu olgu sunumunda sitagliptinkullanımına bağlı gelişmiş olan kutanöz lökositoklastik vaskülitli bir vaka sunulmaktadır. Sitagliptin tip 2 diyabettedavisinde yaygın kullanılmakta olup, hekimlerin bu nadir fakat ciddi ilaç yan etki olasılığının farkında olmalarıgerekmektedir.

Sitagliptin Induced Cutaneous Leukocytoclastic Vasculitis: A Case Report

Sitagliptin is a new generation theurapeutic agent of diabetes mellitus belongs to dipeptidyl peptidase-IV inhibitorclass which acts via the incretin hormone system. The advantages are the absence of hypoglycemia when used asmonotherapy. Trials that reported the weight effects of sitagliptin found modest increases or decreases. The mostcommon side effects of sitagliptin are headache and pharyngitis, and few serious adverse events were observed dur- ing clinical trials. Sitagliptin and metabolites may cause hypersensitivity reactions. Sitagliptin associated cutaneousleukocytoclastic vasculitis has not been described previously in the literature . Here, we report a case of cutaneousleukocytoclastic vasculitis due to probable sitagliptin usage. As sitagliptin is a widely used agent in type 2 diabetesmellitus treatment, physicians should be aware of the possibility of this rare but potentially serious adverse event.

PDF

___

1. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glyce- mia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89:2078-84. 2. Januvia (sitagliptin) tablet [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2007. 3. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipep- tidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:256471. 4. Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Je- remy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman and Barry J Goldstein. Safetyrtand to- lerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. . BMC Endocr Disord 2010;1472-6823,10:7. 5. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, et al.: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14. 6. Shear NH, Knowles SR, Shapiro L. Cutaneous reactions to drugs. In: Woff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Lef- fell DJ, editors. Fitzpatricks dermatology in general medicine. 7th ed. New York: McGraw Hill, 2007:360-361. 7. Russel J P ve Gibson, LE. Primary cutaneous small vessel vascu- litis: approach to diagnosis and treatment. Int J Dermatol 2006, 45, 313. 8. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diag- nostic criteria, classification, epidemiology, etiology, pathogene- sis, evaluation and prognosis. Am J Dermatopathol 2005;27:504- 528. 9. Soter NA, Jose L, Perez D. Cutaneous necrotizing venulitis. In: Woff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatricks dermatology in general medicine. 7th ed. New York: McGraw Hill, 2007:1599-1606. 10. Crowson A N, Mihm M C ve Magro C M. Cutaneous vasculitis: a review. J Cutan Pathol 2003; 30: 161-173.